ANIX
Anixa Biosciences IncCompany Information
- Company Name
- Anixa Biosciences Inc
- CIK
- CIK0000715446
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ANIX: Nasdaq
- Fiscal Year End
- October 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ANIX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-30
- Last sale
- —
- Shares purchased (TTM)
- 151,169
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 5,237,358
- Shares outstanding
- 34,182,000
- Ownership
- 15.32%
Earnings Market Reaction
- Filing date
- 2026-09-09
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Short Term Investments | 12 | 12 | 13 | 14 | 15 | 14 | 16 | 19 | 20 | 22 | 23 | 23 | ||||||
| Receivables Net Current | - | 0 | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | ||||||
| Assets Current | 15 | 15 | 15 | 16 | 17 | 17 | 19 | 21 | 23 | 24 | 25 | 25 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 15 | 15 | 15 | 16 | 18 | 17 | 19 | 22 | 23 | 24 | 25 | 26 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 2 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 273 | 271 | 269 | 267 | 265 | 262 | 261 | 260 | 259 | 258 | 256 | 252 | ||||||
| Retained Earnings Accumulated Deficit | -259 | -257 | -254 | -252 | -249 | -247 | -244 | -241 | -238 | -235 | -231 | -228 | ||||||
| Treasury Stock Value | - | - | - | - | - | - | -0 | -0 | - | - | - | - | ||||||
| Stockholders Equity | 14 | 13 | 14 | 15 | 17 | 15 | 18 | 20 | 22 | 23 | 24 | 23 | ||||||
| Minority Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Liabilities And Stockholders Equity | 15 | 15 | 15 | 16 | 18 | 17 | 19 | 22 | 23 | 24 | 25 | 26 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | ||||||
| Preferred Stock Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 35 | 34 | 33 | 33 | 33 | 32 | 32 | 32 | 32 | 32 | 32 | 31 | ||||||
| Shares Outstanding | 35 | 34 | 33 | 33 | 33 | 32 | 32 | 32 | 32 | 32 | 32 | 31 | ||||||
| Treasury Stock Common Shares | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAnixa Biosciences Inc (ANIX) — SEC Financial Statements & Analysis
Anixa Biosciences Inc (ANIX) is a pharmaceutical preparations company, incorporated in DE. Anixa Biosciences Inc trades on Nasdaq as: ANIX. Anixa Biosciences Inc (ANIX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-07-31, filed with the SEC on 2026-09-09. Based on that filing, Anixa Biosciences Inc carries a market cap of $116.90M, a P/E ratio of -11.28x, a P/B ratio of 8.08x, a P/S ratio of 679.83x, an enterprise value of $115.50M, and an EV/EBITDA multiple of -10.52x. On profitability, it posts an operating margin of -5744.76%, a net margin of -5117.62%, a Return on Equity (ROE) of -66.74%, a Return on Assets (ROA) of -63.36%, and a Return on Invested Capital (ROIC) of -77.92%. Per share, it reports EPS of $-0.30, diluted EPS of $-0.30, free cash flow per share of $-0.22, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -7.93% year-over-year, and EPS growth of -12.53% year-over-year. On the balance sheet, it maintains a current ratio of 8.54x, a quick ratio of 7.94x, working capital of $13.17M, a debt-to-equity ratio of 0.13x, a debt ratio of 0.12, free cash flow of $-7.38M (TTM), and net debt of $-1.40M. Figures sourced from SEC EDGAR.
- Market Cap
- $116.90M
- P/E TTM
- -11.28x
- EPS TTM
- $-0.30
- P/B TTM
- 8.08x
- ROE TTM
- -66.74%
- ROA TTM
- -63.36%
- Debt To Equity
- 0.13x
- Free Cash Flow TTM
- $-7.38M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-07-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Anixa Biosciences Inc in?
Anixa Biosciences Inc (ANIX) operates in the Pharmaceutical Preparations industry.
What exchange does ANIX trade on?
Anixa Biosciences Inc (ANIX) trades on the Nasdaq.
Where is Anixa Biosciences Inc incorporated?
Anixa Biosciences Inc is incorporated in DE.
When was Anixa Biosciences Inc (ANIX)'s most recent SEC filing?
Anixa Biosciences Inc (ANIX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-07-31, filed with the SEC on 2026-09-09.
What is ANIX's market cap?
Anixa Biosciences Inc (ANIX) has a market capitalization of $116.90M as of 2026-07-31.
What is ANIX's EPS (earnings per share)?
Anixa Biosciences Inc (ANIX)'s trailing twelve month EPS is $-0.30 as of 2026-07-31.
What is ANIX's ROE (return on equity)?
Anixa Biosciences Inc (ANIX)'s trailing twelve month Return on Equity (ROE) is -66.74% as of 2026-07-31.
What is ANIX's ROA (return on assets)?
Anixa Biosciences Inc (ANIX)'s trailing twelve month Return on Assets (ROA) is -63.36% as of 2026-07-31.
What is ANIX's ROIC (return on invested capital)?
Anixa Biosciences Inc (ANIX)'s trailing twelve month Return on Invested Capital (ROIC) is -77.92% as of 2026-07-31.
What is ANIX's EV/EBITDA?
Anixa Biosciences Inc (ANIX)'s trailing twelve month EV/EBITDA is -10.52x as of 2026-07-31.